Extensive weight loss can reduce immune age by altering IgG N-glycosylation

Valentina L Greto^{1*}, Ana Cvetko^{2*}, Tamara Štambuk^{3*}, Niall J Dempster⁴, Domagoj Kifer², Helena Deriš³, Ana Cindrić³, Frano Vučković³, Mario Falchi⁵, Richard S Gillies⁶, Jeremy W Tomlinson⁴, Olga Gornik^{2,3}, Bruno Sgromo⁶, Tim D Spector⁵, Cristina Menni^{5*}, Alessandra Geremia^{1*}, Carolina V Arancibia- Cárcamo^{1*}, Gordan Lauc^{2,3*}

 ¹Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, United Kingdom
 ²Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
 ³Genos Glycoscience Research Laboratory, Zagreb, Croatia
 ⁴Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, United Kingdom
 ⁵The Department of Twin Research, King's College London, St Thomas' Hospital, London, United Kingdom
 ⁶Department of Upper Gl Surgery, Oxford University Hospitals, United Kingdom

*The authors equally contributed to this work

Corresponding author:

Gordan Lauc

glauc@pharma.hr

Faculty of Pharmacy and Biochemistry, University of Zagreb

A. Kovačića 1, 10 000 Zagreb, Croatia

1 ABSTRACT

2 Background

3 Obesity represents a global health threat, and is associated not only with exponentially 4 increased cardiometabolic morbidity and mortality, but with adverse clinical outcomes in 5 patients infected with SARS-CoV-2 as well. Enzymatic attachment of complex oligosaccharides 6 to proteins (glycosylation) is highly responsive to numerous (patho)physiological conditions 7 and ageing, which is perhaps best exemplified on IgG. The prospect of immune age reduction, 8 by reverting induced glycosylation changes through metabolic intervention, opens many 9 possibilities. Herein, we have investigated whether weight loss interventions affect 10 inflammation- and ageing-related glycosylation alterations, in a longitudinal cohort of bariatric-surgery patients. To support potential findings, BMI-related glycosylation changes 11 12 were monitored in a longitudinal TwinsUK cohort.

13 Methods

IgG and plasma N-glycans were chromatographically profiled in 37 obese patients, subjected
to low-calorie diet and then to bariatric surgery, across multiple timepoints. Similarly, plasma
glycome was analysed in 1,680 TwinsUK participants and longitudinally monitored during a
20-year follow-up.

18 Findings

19 Low-calorie diet induced marked increase in low branched and significant decrease in highly 20 branched, more complex plasma N-glycans – the change opposite to the one typically 21 observed in inflammatory conditions. Bariatric surgery resulted in extensive, gradual 22 alterations in IgG glycome, that accompanied progressive weight loss during one year follow-23 up. We observed significant increase in digalactosylated and sialylated, and substantial 24 decrease in agalactosylated and core fucosylated IgG glycans. In general, such IgG glycan 25 profile is associated with a younger biological age and reflects enhanced anti-inflammatory 26 IgG potential. The TwinsUK cohort replicated weight loss-associated agalactosylation decrease 27 and digalactosylation increase, estimated through BMI decrease over a 20-year-period.

28 Interpretation

Altogether, these findings highlight that weight loss substantially affects both plasma and IgG
 N-glycosylation, resulting in improved biological and immune age.

- 31
- -
- 32

33 GRAPHICAL ABSTRACT





54 N-glycosylation; bariatric surgery; weight loss; imunoglobulin G; COVID-19; biological age

55 **INTRODUCTION**

56 The global prevalence of obesity has risen dramatically, to the point that it is now considered 57 a pandemic (1). In the current collision with the emergent coronavirus disease (COVID-19 58 pandemic), there is a strong association of obesity and older age with COVID-19 complications 59 and severity (2). According to the World Health Organization, over 650 million individuals are 60 obese, accounting for the 13% of the world's adult population. Obesity confers a risk for 61 metabolic syndrome, contributing to type 2 diabetes and cardiovascular disease (CVD) 62 development (3). Metabolic syndrome is linked to a chronic systemic low-grade inflammation, 63 which contributes to the aging of the immune system denoted as inflammaging (4,5). Obesityrelated inflammaging results in impaired innate and adaptive immune function, and is 64 65 characterized by high serum levels of IL-6, TNF- α and CRP (6). Moreover, this persistent 66 inflammatory state may potentially lead to increased viral shedding and to delayed, blunted 67 antiviral responses to SARS-CoV-2 infection (7,8).

68 Changes in protein N-glycosylation are one of the hallmarks of inflammaging (5,8). The human 69 circulating N-glycome represents the entire set of glycans that are covalently attached to 70 plasma proteins through a nitrogen on an asparagine residue. N-glycans are essential for life 71 and are involved in many physiological processes (9), including signal transduction, protein 72 trafficking and folding, receptor regulation and cell adhesion. Glycosylation has a fundamental 73 role in the innate and adaptive immune responses, accentuated by the fact that all five classes 74 of immunoglobulins (Ig) bear N-glycans. In this regard, IgG is probably the most investigated 75 glycoprotein, whose effector functions are controlled by its Fc-bound glycans (10).

76 Inter-individual differences in the pace of biological ageing is an intriguing concept that tries 77 to explain why some people stay healthy until very late chronological age, while others age 78 faster and have shorter life expectancy. The same may apply for the risk of severe COVID-19. 79 Progressive age-related changes of IgG glycosylation have been extensively studied (9,11,12), 80 and the GlycanAge model has been proposed to express the difference between chronological 81 ageing and IgG glycome ageing (13). The "age" of the IgG glycome might be estimated through 82 the levels of agalactosylated species, which are increasing with ageing and are associated with 83 enhanced immune activation (14). The opposite applies for digalactosylated IgG glycoforms, 84 which are usually related to a younger age. Besides age-related changes, specific IgG glycosylation patterns have been already associated with CVD risk score and subclinical 85 atherosclerosis in two large independent UK cohorts (15). Moreover, a prospective follow-up 86

of the EPIC-Potsdam cohort confirmed that changes in plasma N-glycome composition are predictive of future CVD events, with comparable predictive power to the American Heart Association (AHA) score in men and even better predictive power in women (16). The link between an "old", proinflammatory IgG N-glycome and hypertension has also been profoundly studied (17–19), and similar IgG glycosylation patterns were associated with increased body mass index (BMI) and measures of central adiposity (20,21).

93 Studies on mouse models further corroborate the importance of differential IgG glycoforms 94 in CVD pathogenesis. Namely, it has been shown that hyposialylated IgG (corresponding to an 95 "old" IgG glycome) can induce obesity-related hypertension and insulin resistance in B-cell-96 deficient mice, through activation of the endothelial FcyRIIB (22,23). These findings indicate 97 that the IgG N-glycome could represent more than a biomarker of inflammation and aging, 98 since distinctive IgG glycoforms act as effector molecules in certain pathologies. Furthermore, 99 supplementation with N-acetylmannosamine (ManNAc), a precursor of sialic acid, protects 100 obese mice from hypertension and insulin resistance induction by reverting an "old" IgG N-101 glycome into a "young" one (23,24). However, studies exploring the possibilities of converting 102 an "old" IgG glycome into a "young" one by metabolic intervention in humans are limited. Of 103 note, only one small study indicated that high-intensity interval training can "rejuvenate" the 104 IgG N-glycome (25).

105 Finally, severe obesity can be resolved only through bariatric surgery and subsequent weight loss (26). The resulting weight loss impacts energy balance and metabolism, contributing to 106 107 the increased insulin response, improved glycaemic control and reduction of total body fat, 108 leading to decreased CVD risk and mortality (27). In this study we aimed to determine whether 109 weight loss affects glycan markers related to inflammation and ageing, in a longitudinally-110 monitored cohort of obese individuals undergoing low-calorie diet and then bariatric surgical 111 interventions. In order to support potential findings, we also investigated the BMI-related glycosylation changes in a longitudinal TwinsUK cohort. The analysis of samples obtained from 112 113 the largest longitudinal twins cohort in the UK allowed us to observe the changes of BMI in 114 relation to the IgG N-glycosylation alterations over time.

- 115
- 116 **METHODS**
- 117 Study populations

118 *Bariatric cohort*. The cohort included 37 participants, recruited at Oxford University Hospitals

to the Gastrointestinal Illnesses study (Ref: 16/YH/0247). All patients were characterised by

120 metabolic status and medical history. Bariatric patients were considered eligible in accordance

- to National Institute for Health and Care Excellence (NICE) and local guidelines. The choice of
- 122 bariatric operation was decided according to the Oxford Bariatric Unit regular practice.
- 123 Patients with a history of alcoholism and/or ongoing anticoagulant treatment were excluded.
- 124 Patients were also excluded in case of pregnancy, active substance abuse or uncontrolled
- 125 psychiatric condition including eating disorders. Participants were sampled at baseline and
- 126 subjected to 3-week low calorie carbohydrate-restricted diet (900 cal, maximum 100 g of
- 127 carbohydrates per day), followed by bariatric surgery. The sequential follow-up timepoints
- 128 included the day of the surgery (baseline), after 6.54 \pm 3.4 months (mean \pm IQR) and 12.47 \pm
- 129 6.55 months post-op. Characteristics of the bariatric cohort are shown in Table 1.

Characteristics	Bariatric cohort				
Total No. of participants	37				
(N)					
No. of participants Sleeve	25 (68%)				
Gastrectomy (SG), N (%)					
No. Roux-en-Y Gastric	12 (32%)				
Bypass RYGB N (%)					
No. of participants each	Pre-op low-calorie diet		Time of	1st post-op	2 nd post-op
timepoint (N)			surgery	timepoint	timepoint
	8		37	30	24
BMI* each timepoint,	Before diet	End of diet	Time of	1 st post-op	2 nd post-op
mean ± SD, kg/m2			surgery	timepoint	timepoint
	48.53 ± 4.13	46.60± 4.21	46.21 ± 4.75	36.01 ± 5.07	32.82 ± 5.17
Female, sex, N (%)	33 (89%)				
Type 2 diabetes, N (%)	6 (16%)				

130 Table 1 Demographic characteristics of the bariatric cohort

131

*BMI reference values: <18.5 (underweight), 18.5–24.9 (normal weight), 25–29.9
(overweight), >30 (obese).

134

135 <u>*TwinsUK cohort.*</u> We have analysed a total of 6,032 plasma samples from 2,146 participants of 136 the TwinsUK study, collected at multiple timepoints over a 20 year-period (28). These included 137 1,865 individuals sampled at 3 timepoints, 156 individuals sampled at 2 timepoints and 125 138 individuals sampled only once. Following the plasma N-glycome analysis, glycan data 139 underwent quality control (see *Statistical analysis* section), which decreased the dataset to 5,889 samples (measurements). Out of these 5,889 measurements, we have proceeded with

- 141 statistical analysis on a subset of 3,742 samples (measurements) which had information on
- 142 BMI available. Description of the TwinsUK cohort is provided in Table 2.
- 143

144 Table 2 Demographic characteristics of the TwinsUK cohort

Characteristics	TwinsUK cohort (BMI subset)
No. of participants (N)	1,680
No. of glycan measurements (N)	3,742
Baseline age, mean ± SD, years	53.23 ± 10.86
Follow up time, mean ± SD, years	7.90 ± 5.66
Female sex, N (%)	1,680 (100)
Baseline BMI, mean ± SD, kg/m ²	25.45 ± 4.53

145

146 **Ethical statement**

Ethical approval for the study was obtained by the National Research Ethics Committees of the UK National Health Service (NHS) under the reference number 16/YH/0247. All individuals participating in this study gave written informed consent. The TwinsUK study was approved by NRES Committee London–Westminster, and all twins provided informed written consent.

151 N-glycome analysis

152 Isolation of IgG from human plasma

IgG was isolated from plasma samples by affinity chromatography as described previously (29). In brief, IgG was isolated in a high-throughput manner, using 96-well protein G monolithic plates (BIA Separations, Slovenia), starting from 100 μl of plasma. Plasma was diluted 7× with phosphate buffered saline (PBS; Merck, Germany) and applied to the protein G plate. IgG was eluted with 1 ml of 0.1 M formic acid (Merck, Germany) and immediately neutralized with 1 M ammonium bicarbonate (Acros Organics, USA).

- 159 <u>N-glycan release from IgG and total plasma proteins</u>
- 160 Isolated IgG samples were dried in a vacuum centrifuge. After drying, IgG was denatured with 161 the addition of 30 μ l of 1.33% SDS (w/v) (Invitrogen, USA) and by incubation at 65 °C for 10 162 min. Plasma samples (10 μ l) were denatured with the addition of 20 μ l of 2% (w/v) SDS 163 (Invitrogen, USA) and by incubation at 65 °C for 10 min. From this point on, the procedure was
- identical for both IgG and plasma samples. After denaturation, 10 μ l of 4% (v/v) Igepal-CA630

(Sigma Aldrich, USA) was added to the samples, and the mixture was shaken 15 min on a plate
shaker (GFL, Germany). N-glycans were released with the addition of 1.2 U of PNGase F

167 (Promega, USA) and overnight incubation at 37 °C.

168 *Fluorescent labelling and HILIC SPE clean-up of released N glycans*

169 The released N-glycans were labelled with 2-aminobenzamide (2-AB). The labelling mixture 170 consisted of 2-AB (19.2 mg/ml; Sigma Aldrich, USA) and 2-picoline borane (44.8 mg/ml; Sigma 171 Aldrich, USA) in dimethyl sulfoxide (Sigma Aldrich, USA) and glacial acetic acid (Merck, 172 Germany) mixture (70:30 v/v). To each sample 25 μ l of labelling mixture was added, followed 173 by 2 h incubation at 65 °C. Free label and reducing agent were removed from the samples 174 using hydrophilic interaction liquid chromatography solid-phase extraction (HILIC-SPE). After 175 incubation samples were brought to 96% of acetonitrile (ACN) by adding 700 µl of ACN (J.T. 176 Baker, USA) and applied to each well of a 0.2 µm GHP filter plate (Pall Corporation, USA). 177 Solvent was removed by application of vacuum using a vacuum manifold (Millipore 178 Corporation, USA). All wells were prewashed with 70% ethanol (Sigma-Aldrich, St. Louis, MO, 179 USA) and water, followed by equilibration with 96% ACN. Loaded samples were subsequently 180 washed $5 \times$ with 96% ACN. N-glycans were eluted with water and stored at – 20 °C until usage.

181 <u>Hydrophilic interaction liquid chromatography of N glycans</u>

182 Fluorescently labelled N-glycans were separated by hydrophilic interaction liquid 183 chromatography (HILIC) on Acquity UPLC H-Class instrument (Waters, USA) consisting of a 184 quaternary solvent manager, sample manager and a fluorescence detector, set with excitation 185 and emission wavelengths of 250 and 428 nm, respectively. The instrument was under the 186 control of Empower 3 software, build 3471 (Waters, Milford, USA). Labelled N-glycans were 187 separated on a Waters BEH Glycan chromatography column, with 100 mM ammonium 188 formate, pH 4.4, as solvent A and ACN as solvent B. In the case of IgG N-glycans, separation 189 method used linear gradient of 75–62% acetonitrile at flow rate of 0.4 ml/min in a 27-min 190 analytical run. For plasma protein N-glycans separation method used linear gradient of 70-191 53% acetonitrile at flow rate of 0.561 ml/min in a 25-min analytical run. The system was 192 calibrated using an external standard of hydrolysed and 2-AB labelled glucose oligomers from 193 which the retention times for the individual glycans were converted to glucose units (GU). 194 Data processing was performed using an automatic processing method with a traditional 195 integration algorithm after which each chromatogram was manually corrected to maintain 196 the same intervals of integration for all the samples. The chromatograms were all separated

197 in the same manner into 24 peaks (GP1– GP24) for IgG N-glycans and 39 peaks (GP1–GP39) 198 for plasma protein N-glycans and are depicted in Supplementary Figure 1 and Supplementary 199 Figure 2, respectively. Detailed description of glycan structures corresponding to each glycan 200 peak is presented in Supplementary Table 1. Glycan peaks were analysed based on their 201 elution positions and measured in glucose units, then compared to the reference values in the 202 "GlycoStore" database (available at: https://glyco store .org/) for structure assignment. The 203 amount of glycans in each peak was expressed as a percentage of the total integrated area. 204 For IgG glycans, in addition to 24 directly measured glycan traits, 8 derived traits were 205 calculated, while for plasma glycans, in addition to 39 directly measured glycan traits, 16 206 derived traits were also calculated. These derived traits average particular glycosylation 207 features, such as galactosylation, fucosylation, bisecting GlcNAc, and sialylation. Formulas for 208 IgG and plasma protein N-glycan derived traits for bariatric cohort are presented in 209 Supplementary Table 2 and Supplementary Table 3, respectively. Derived trait calculations for 210 TwinsUK cohort are presented in Supplementary Table 4.

211 Statistical analysis

212 Bariatric cohort. In order to remove experimental variation from the measurements, 213 normalization and batch correction were performed on the UPLC glycan data. To make 214 measurements across samples comparable, normalization by total area was performed. Prior 215 to batch correction, normalized glycan measurements were log-transformed due to right-216 skewness of their distributions and the multiplicative nature of batch effects. Batch correction 217 was performed on log-transformed measurements using the ComBat method (R package sva 218 (30), where the technical source of variation (which sample was analysed on which plate) was 219 modelled as batch covariate. To correct measurements for experimental noise, estimated 220 batch effects were subtracted from log-transformed measurements.

Longitudinal analysis of patient samples through their observation period was performed by implementing a linear mixed effects model, where time was modelled as fixed effect, while the individual ID was modelled as random effect. Prior to the analyses, glycan variables were all transformed to standard Normal distribution by inverse transformation of ranks to Normality (R package "GenABEL", function rntransform). Using rank transformed variables makes estimated effects of different glycans comparable, as these will have the same standardized variance. False discovery rate (FDR) was controlled by the Benjamini-Hochberg

228 procedure at the specified level of 0.05. Data was analysed and visualized using R 229 programming language (version 3.5.2)(31).

230 TwinsUK cohort. Normalization of peak intensities to the total chromatogram area was 231 performed for each measured sample separately. Calculated proportions were then batch corrected using ComBat method (R package sva)(30). After the batch correction the first 11 232 233 peaks, which predominantly originate from IgG (32), were used to calculate 6 derived glycan 234 traits – agalactosylation (G0), monogalactosylation (G1), digalactosylation (G2), bisecting 235 GlcNAc (B), core fucosylation (CF) and high mannose structures (HM). Mixed models were 236 fitted to estimate the effect of BMI change on IgG N-glycome (R package Ime4)(33). Directly 237 measured or derived glycan trait was used as a dependent variable in the mixed model. To 238 differentiate between BMI change and the absolute BMI value, the variable was separated to 239 $BMI_{baseline}$ and $BMI_{difference}$ (calculated according to the following equation: $BMI_{difference}$ = 240 BMI_{follow up age} – BMI_{baseline age}), and both were used in the model as a fixed effect. Since 241 IgG N-glycome is affected by aging, age was included both as a fixed effect and a random 242 slope. Finally, to meet the independency criteria, family ID and individual ID (nested within 243 family) were included in the model as a random intercept. Due to multiple model fitting (for 244 11 directly measured and 6 derived glycan traits) false discovery rate was controlled using 245 Benjamini-Hochberg method. All statistical analyses were performed using R programming 246 language (version 3.6.3)(31).

247 248

249 **RESULTS**

250 *Pre-surgical low-calorie diet extensively changes plasma N-glycome*

251 We profiled both plasma and IgG N-glycome in a cohort of bariatric surgery-candidate patients 252 at the beginning and at the end of their pre-operative diet. We calculated corresponding 253 derived glycan traits, which average particular glycosylation features. By employing a linear 254 mixed model, we observed ample changes in plasma N-glycome, as 10 out of 16 calculated derived traits displayed significant alterations after the low-calorie diet. Namely, low 255 256 agalactosylated (G0), monogalactosylated (G1), asialylated (S0), branched (LB), 257 monosialylated (S1), core fucosylated (CF) and glycans bearing a bisecting GlcNAc (B) showed 258 a substantial increase in their abundances (Table 3). Conversely, high branched (HB), 259 trisialylated (S3) and trigalactosylated (G3) glycan abundances decreased (Table 3).

- 260 Interestingly, IgG glycome was not affected by the low-calorie diet, as its derived traits did not
- 261 display any significant changes after the dieting period. Graphical representation of the
- longitudinal alterations in plasma N-glycome after low calorie diet are depicted in Figure 1.
- 263
- 264 **Table 3 Low-calorie diet induces significant changes in plasma N-glycome**. Longitudinal
- analysis was performed by implementing a linear mixed effects model, with time as a fixed
- 266 effect and the individual sample measurement as a random effect. False discovery rate was
- controlled using Benjamini-Hochberg method at the specified level of 0.05.

Derived glycan trait	Time_effect	Time_SE	Time_p-value	Adjusted p-value
monogalactosylation (G1)	0.6020	0.0796	4.18 x10 ⁻⁰⁵	6.69 x10 ⁻⁰⁴
trisialylation (S3)	-1.1512	0.2008	3.04 x10 ⁻⁰⁴	2.43 x10 ⁻⁰³
agalactosylation (G0)	0.4903	0.0948	6.09 x10 ⁻⁰⁴	2.44 x10 ⁻⁰³
core fucosylation (CF)	0.5431	0.1011	4.73 x10 ⁻⁰⁴	2.44 x10 ⁻⁰³
high branching (HB)	-1.1925	0.2468	9.43 x10 ⁻⁰⁴	2.52 x10 ⁻⁰³
asialylation (S0)	0.6336	0.1310	9.40 x10 ⁻⁰⁴	2.52 x10 ⁻⁰³
trigalactosylation (G3)	-1.1925	0.2581	1.24 x10 ⁻⁰³	2.84 x10 ⁻⁰³
bisecting GlcNAc (B)	0.5457	0.1350	2.84 x10 ⁻⁰³	5.69 x10 ⁻⁰³
low branching (LB)	0.9839	0.3060	9.99 x10 ⁻⁰³	1.78 x10 ⁻⁰²
monosialylation (S1)	0.5024	0.1981	2.98 x10 ⁻⁰²	4.77 x10 ⁻⁰²
disialylation (S2)	-0.4314	0.1941	4.99 x10 ⁻⁰²	7.25 x10 ⁻⁰²
high mannose (HM)	0.7545	0.3619	6.24 x10 ⁻⁰²	8.33 x10 ⁻⁰²
antennary fucosylation (AF)	-0.1804	0.1102	1.28 x10 ⁻⁰¹	1.58 x10 ⁻⁰¹
digalactosylation (G2)	0.3107	0.2309	2.01 x10 ⁻⁰¹	2.30 x10 ⁻⁰¹
tetragalactosylation (G4)	-0.3446	0.3477	3.36 x10 ⁻⁰¹	3.58 x10 ⁻⁰¹
tetrasialylation (S4)	-0.3049	0.3547	4.00 x10 ⁻⁰¹	4.00 x10 ⁻⁰¹

- 268 Red significant decrease; green significant increase; blue non-significant change.
- 269 GlcNAc *N*-acetylglucosamine; SE standard error



271

Figure 1 Low calorie diet-related alterations in plasma N-glycome after a 3-week follow-up.
 Red line – significant decrease; green line – significant increase; blue line – non-significant
 change.

275 Bariatric surgery markedly alters IgG N-glycosylation

276 Using the same chromatographic approach, we analysed samples from patients who 277 underwent bariatric surgery. The plasma samples were collected on the day of surgery (month 278 0), approximately 6 months post-surgery and 12 months post-surgery. Both plasma and IgG 279 N-glycans were profiled in each of these timepoints, and the obtained values were used for 280 derived glycan traits calculations. Of the examined plasma glycosylation features, only 281 agalactosylation (G0) displayed significant decrease after bariatric surgery (Table 4). On the 282 other hand, IgG N-glycome showed more extensive changes, following the bariatric 283 procedure. Namely, four out of eight tested derived traits showed marked changes: core 284 fucosylated (CF) and agalactosylated (GO) glycans decreased, while digalactosylated (G2) and 285 monosialylated (S1) glycans increased after the surgery (Table 4). The IgG glycans whose 286 abundances were increased after bariatric surgery are major components of a "young" IgG 287 glycome, as they are typically associated with a younger age. The opposite applies to agalactosylated structures, which are usual denominators of an "old" IgG glycome profile. We 288 289 also examined the correlation of patients' clinical data with plasma and IgG glycome features 290 using multivariate analysis, but found no statistically significant associations (data not shown). 291 Finally, the type of bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) 292 did not affect plasma nor IgG glycome composition. Graphical representations of the 293 longitudinal alterations in IgG and plasma glycosylation features are depicted in Figure 2 and 294 Supplementary Figure 3, respectively.

295

296 Table 4 Bariatric surgery induces significant changes in plasma and IgG N-glycomes.

297 Longitudinal analysis was performed by implementing a linear mixed effects model, with

time as a fixed effect and the individual sample measurement as a random effect. False

299 discovery rate was controlled using Benjamini-Hochberg method at the specified level of

300 0.05.

N-glycome	Derived glycan trait	Time_effect	Time_SE	Time_p-value	Adjusted p-value
plasma	agalactosylation (G0)	-0.0273	0.0071	5.26x10 ⁻⁰⁴	8.42x10 ⁻⁰³
lgG	agalactosylation (G0)	-0.0339	0.0078	9.23x10 ⁻⁰⁵	7.38x10 ⁻⁰⁴
lgG	digalactosylation (G2)	0.0275	0.0072	3.75x10 ⁻⁰⁴	1.50x10 ⁻⁰³
lgG	monosialylation (S1)	0.0193	0.0080	1.97x10 ⁻⁰²	3.94x10 ⁻⁰²
lgG	core fucosylation (CF)	-0.0155	0.0064	1.74x10 ⁻⁰²	3.94x10 ⁻⁰²

301 Red – significant decrease; green – significant increase. SE – standard error.

302

303



Figure 2 Bariatric surgery-related alterations in IgG N-glycome over time (months). Red line
 - significant decrease; green line - significant increase; blue line - non-significant change.

308

305

309 Weight loss induces shift towards "young" IgG N-glycome

310 Using the same chromatographic approach, we profiled plasma protein N-glycome from 1,680 311 TwinsUK study participants sampled at several timepoints over a 20-year-period. This served 312 as a replication of the findings from the bariatric cohort, whose participants exhibited the 313 reversal from "old" to "young" IgG N-glycome due to weight loss. As these results showed 314 prominent changes in IgG composite glycan traits only, herein we focused on IgG glycosylation 315 changes. Due to the fact that for TwinsUK cohort plasma glycome was profiled, we calculated 316 derived traits and performed statistical analysis only on the first 11 glycan peaks, 317 corresponding to the glycans predominantly originating from IgG (32). Six derived traits were 318 calculated – agalactosylation (G0), monogalactosylation (G1), digalactosylation (G2), 319 incidence of bisecting GlcNAc (B), core fucosylation (CF) and incidence of high mannose 320 structures (HM). We examined IgG glycome alterations associated with changes in BMI using 321 a mixed model on a subset of 3,742 samples. Out of six examined IgG glycosylation features

322 (derived traits), three displayed significant BMI-related changes – agalactosylation (G0), 323 digalactosylation (G2) and incidence of high mannose structures (HM) (Table 5). Namely, the 324 abundance of digalactosylated (G2) glycans increased with the BMI decrease, while the 325 abundance of agalactosylated (G0) and high mannose glycans (HM) decreased with the weight 326 loss, estimated by the BMI drop. These findings are in line with the results observed in the 327 bariatric surgery cohort. Graphical representation of the longitudinal BMI-dependent 328 alterations of IgG glycosylation are depicted at Figure 3.

329

330 Table 5 Longitudinally monitored weight loss results with significant changes of IgG N-

331 glycosylation. Longitudinal analysis was performed by implementing a mixed model, fitted
 332 to estimate the effect of BMI change on IgG N-glycome. False discovery rate was controlled

- 222 to estimate the effect of Divit change of igo in-grycome. Taise discovery rate was controlled
- using Benjamini-Hochberg method at the specified level of 0.05.

Derived glycan trait	BMI difference effect (glycan abundance (%) change per 1 kgm ⁻² decrease in BMI)	BMI difference SE (glycan abundance (%) change per 1 kgm ⁻² decrease in BMI)	p-value	Adjusted p-value
digalactosylation (G2)	0.2004	0.0403	6.88x10 ⁻⁰⁷	5.85 x10 ⁻⁰⁶
high mannose (HM)	-0.0519	0.0119	1.33x10 ⁻⁰⁵	5.66 x10 ⁻⁰⁵
agalactosylation (G0)	-0.1048	0.0397	8.43x10 ⁻⁰³	1.79 x10 ⁻⁰²
bisecting GlcNAc (B)	0.0526	0.0262	4.49x10 ⁻⁰²	6.94x10 ⁻⁰²
monogalactosylation (G1)	-0.0573	0.0343	9.53x10 ⁻⁰²	1.25x10 ⁻⁰¹
core fucosylation (CF)	-0.0059	0.0285	8.36x10 ⁻⁰¹	8.89x10 ⁻⁰¹

Red – significant decrease; green – significant increase; blue – non-significant change.

335 GlcNAc – *N*-acetylglucosamine; SE – standard error





337 Figure 3 BMI-associated alterations in IgG N-glycosylation across multiple timepoints. 338 Changes in IgG derived traits are presented with lineplots of hypothetical ageing of TwinsUK 339 participants (all women). Black dot represents a starting point of a 30-year-old woman, black 340 triangle of a 40-year-old woman and black square of a 50-year-old woman. All of these women have a baseline BMI of 25 kg m⁻². Blue lines represent age-related IgG glycosylation changes 341 attributed to stabile BMI. Green lines represent age-related IgG glycosylation changes 342 attributed to increasing BMI (0.5 kg m⁻² per year, through a period of 10 years). Red lines 343 represent age-related IgG glycosylation changes attributed to decreasing BMI (0.5 kg m⁻² per 344 345 year, through a period of 10 years). Highlighted areas represent 95% confidence intervals. The 346 effect of age on IgG glycosylation is represented with the curve slope, while the effect of BMI 347 change is represented with the distance of green/red line from the blue line.

348

350

349 **DISCUSSION**

In this study, we have observed extensive changes in both plasma and IgG N-glycome associated with weight loss following low-calorie diet and bariatric surgery, or expressed through BMI decrease. To the best of our knowledge, this is the first study to investigate

plasma and IgG N-glycome alterations in patients who underwent a low-calorie diet followedby bariatric surgery.

356 Prior to bariatric surgery, patients were subjected to a low-calorie diet which caused 357 significant and extensive changes to the plasma protein N-glycome. The observed changes can 358 be summarized as significant increase in low-branched, biantennary structures (S0, S1, G0, 359 G1...) and, conversely, substantial decrease in high-branched, triantennary, more complex 360 structures (S3, G3). The glycosylation alterations induced by a low-calorie diet are showing 361 exactly the opposite direction of change than those seen in various inflammatory conditions, 362 such as type 2 diabetes, chronic obstructive pulmonary disease and inflammatory bowel 363 disease (16,29,34,35), suggesting a gradual attenuation of inflammation. Interestingly, no 364 significant changes were found for the IgG N-glycome alone after the diet, probably due to 365 the relatively short follow-up period (3 weeks), which matches IgG serum half-life. Altogether, 366 our glycomic data suggest that the overall inflammatory body status improves after a short 367 time of low-calorie diet, reflecting a quickly noticeable and beneficial metabolic effect.

368

369 We have analysed both plasma and IgG N-glycome from individuals who underwent bariatric 370 surgery, in a longitudinal manner. We observed significant changes in both plasma and IgG N-371 glycome. In particular, plasma N-glycome showed significant alterations only in 372 agalactosylated (GO) glycans, whose abundance decreased during the follow-up period. Since 373 the majority of agalactosylated species in plasma originates from IgG (32), it is no surprise that 374 this glycosylation feature was also found to be significantly decreased in IgG glycome analysis. 375 Elevated levels of G0 IgG glycoforms are typically associated with aging, a pro-inflammatory 376 IgG glycan profile and various inflammatory diseases (11). On the other hand, the levels of 377 digalactosylated (G2) glycans increased after bariatric surgery and at sequential timepoints, in 378 accordance with a reduced inflammatory potential of the circulating IgG. Interestingly, the 379 increased levels of IgG galactosylation are associated with a younger biological age and are 380 considered, in a way, as a measure of an individual's well-being (14). Converesely, IgG 381 galactosylation levels substantially decrease with ageing and during inflammation (11,13). Our 382 results demonstrate that weight loss, resulting from bariatric surgery, can initiate the reversal 383 from an "old" to a "young" IgG N-glycome, potentially reversing the clock for the 384 immune/biological age. Furthermore, bariatric surgery also resulted in significant IgG glycome alteration inducing a decrease in core fucosylation. The vast majority of circulating IgG 385

386 molecules bears core fucose (approximately 95%), which profoundly decreases IgG binding 387 affinity to FcyRIIIA receptor and sequential antibody-dependent cellular cytotoxicity (ADCC) 388 (36). ADCC is largely mediated by natural killer cells that can lyse target cells and fight viral 389 infections. This would suggest that an extensive weight loss ameliorates immune responses 390 dedicated to combat viral infections, by altering IgG glycosylation and modulating its effector 391 functions. Lastly, bariatric surgery-related weight loss led to an increase in IgG sialylation, 392 which is the main modulator of the IgG anti-inflammatory actions (37). In addition to its anti-393 inflammatory actions, the level of IgG sialylation has been implicated in the pathogenesis of 394 obesity-induced insulin resistance and hypertension, as already mentioned (22,23). Namely, 395 inhibitory IgG receptor FcyRIIB was found to be expressed in the microvascular endothelium. 396 Sequentially, it was shown that hyposialylated IgG acts as its operating ligand, leading to the 397 induction of obesity-related insulin resistance and hypertension. On the other hand, the 398 sialylated glycoform is not activating the signalling pathways responsible for the insulin 399 resistance and hypertension development, but is rather preserving insulin sensitivity and 400 normal vasomotor tone, even in obese mice. Interestingly, the same group made another 401 significant discovery – promotion of IgG sialylation breaks the link between obesity and 402 hypertension/insulin resistance (23,24). Namely, supplementation with the sialic acid 403 precursor restored IgG sialylation, highlighting a potential approach to improve both 404 metabolic and cardiovascular health in humans, with a single intervention. Our data suggest 405 that a similar effect might be achieved by weight loss interventions, through restoring of IgG 406 sialylation levels. Altogether, it is quite fascinating that such marked effects could be observed 407 on a rather small number of participants, which further highlights their significance in a given 408 biological setting.

409

410 Lastly, in order to confirm the effects of weight loss on the biological/immune age, we 411 investigated how BMI decrease affects IgG N-glycome during a 20-year-period. We observed 412 the prominent inverse changes of agalactosylated (G0) and digalactosylated (G2) IgG glycans. 413 Namely, agalactosylated IgG glycans significantly decreased, while digalactosylated ones 414 substantially increased as the BMI decreased. These observations corroborated our earlier 415 findings, confirming that the body weight reduction reverses IgG glycome from "old" to 416 "young", implying at the same time a likely reduction in the biological/ immune age. 417 Nonetheless, we have to acknowledge the following limitations of TwinsUK as a replication

418 cohort: first – TwinsUK participants have not experienced such an extensive weight loss, which 419 potentially influenced the replication of other significant glycan changes from the bariatric 420 cohort; second – herein, the weight loss was approximated by BMI decrease, which is usually 421 a legitimate assumption, however, it does not have to apply to all cases; and third – herein we 422 profiled plasma glycome, while the IgG glycan traits were only approximated and the 423 information on IgG sialylation was confounded by other plasma glycoproteins. Ideally, these 424 issues could be circumvented in the future studies whose experimental design would allow 425 the simultaneous, multi-centre follow-up of larger groups of patients.

426 Intense physical exercise can also shift IgG N-glycome towards a "younger" profile by 427 increasing IgG galactosylation (25). Although another study reported that prolonged intensive 428 exercise can have the opposite effect and promote pro-inflammatory changes of IgG N-429 glycome (38), its findings are not surprising since it recruited healthy, normal-weight female 430 participants, subjected to the intense energy deprivation and exercise levels, to induce 431 substantial fat loss in a rather short time period. The authors also highlighted that starting 432 weight and the way in which weight loss is achieved could be crucial for the final effect on the immune system. Therefore, it seems that exercise overall has a positive impact on the immune 433 434 system and biological clock, but its intensity and duration should be personalized in order to 435 provide the optimal results.

436 To summarize, our results indicate that weight loss has impact on inflammation and biological 437 aging by altering plasma and IgG N-glycosylation patterns. Glycosylation changes can be 438 reliably quantified and used to estimate the "age" of the immune system. This could represent 439 a valuable tool in the context of COVID-19 patient stratification. Since inter-individual 440 variation in protein glycosylation is extensive, its functional implications on membrane 441 expression of various proteins (including ACE2), functional properties of newly synthesized 442 SARS-CoV-2 virus particles and regulation of the immune responses may also explain severe 443 cases of COVID-19 in apparently healthy individuals. A previous research showed that 444 impairment of ACE2 N-glycosylation affects its ability to allow the transduction of SARS Human 445 coronavirus NL63 (HCoV-NL63) particles, by disrupting the viral endocytosis (39).

Future glycomic studies of patients infected with SARS- CoV-2 would help to elucidate whether
ACE2 N-glycosylation differs in patients with severe COVID-19, compared to asymptomatic
patients or healthy individuals.

449

450 ACKNOWLEDGMENTS

The authors thank Rachel Franklin, Michelle Haylock, James Chivenga, Roxanne Williams and
Krishnageetha Manoharan for the samples collection and biobanking. The authors thank all
the patients who took part in this study.

454

455 FUNDING

456 Glycosylation analysis was performed in Genos Glycoscience Research Laboratory and partly 457 supported by the European Union's Horizon 2020 grants Backup (grant# 777090), European 458 Structural and Investment Funds IRI grant (#KK.01.2.1.01.0003), Centre of Competence in Molecular Diagnostics (#KK.01.2.2.03.0006) and Croatian National Centre of Research 459 460 Excellence in Personalized Healthcare grant (#KK.01.1.1.01.0010). Bariatric research was 461 supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research 462 Centre Gastroenterology and Mucosal Immunity Theme to CVA-C and VLG, Oxford Biomedical 463 Research Centre Diabetes and Metabolism theme for JWT, MRC programme grant to JWT (ref. 464 MR/P011462/1), the NIHR Research Capability Funding to VLG and AG, the Wellcome Trust (101734/Z/13/Z) to AG. NJD is supported by a University of Oxford Novo Nordisk Clinical 465 466 Research Fellowship. TwinsUK received funding from the Wellcome Trust European 467 Community's Seventh Framework Programme (FP7/2007-2013 to TwinsUK); the National 468 Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust and the Nottingham NIHR Biomedical Research Centre based at Guy's and 469 St Thomas' NHS Foundation Trust and King's College London. CM is funded by the MRC AimHy 470 471 (MR/M016560/1) project grant and by the Chronic Disease Research Foundation.

472

473 AUTHOR'S CONTRIBUTION

Study design: CM, AG, CVA-C, GL. Data collection: VLG, ACv, TŠ, NJD, ACi, HD, MF, CM. Data
analysis: DK, FV. Data interpretation: VLG, ACv, TŠ, NJD, DK, FV, MF, JWT, OG, TS, CM, AG,
CVA-C, GL. Drafting manuscript: VG, ACv, TŠ, NJD, DK, FV, GL. Revising and approving final
version of manuscript: ALL. CM, AG, CVA-C and GL take responsibility for the integrity of the
data analysis

- 479
- 480

481 **REFERENCES**

- 482 1. Obesity and overweight [Internet]. [cited 2020 Apr 16]. Available from:
 483 https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
- Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, et al. Factors
 associated with hospitalization and critical illness among 4,103 patients with COVID-19
 disease in New York City. medRxiv. 2020 Apr 11;2020.04.08.20057794.
- 487 3. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and
 488 cardiovascular disease. JRSM Cardiovasc Dis. 2016 Dec;5:2048004016633371.
- 489 4. Alpert A, Pickman Y, Leipold M, Rosenberg-Hasson Y, Ji X, Gaujoux R, et al. A clinically
 490 meaningful metric of immune age derived from high-dimensional longitudinal
 491 monitoring. Nat Med. 2019 Mar;25(3):487–95.
- 492 5. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new
 493 immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology.
 494 2018 Oct;14(10):576–90.
- 495 6. Touch S, Clément K, André S. T Cell Populations and Functions Are Altered in Human
 496 Obesity and Type 2 Diabetes. Curr Diab Rep. 2017 Sep;17(9):81.
- 497 7. Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev.
 498 2015 Dec;16(12):1017–29.
- Lauc G, Sinclair D. Biomarkers of biological age as predictors of COVID-19 disease
 severity. Aging [Internet]. 2020 Apr 8 [cited 2020 Apr 14]; Available from:
 http://www.aging-us.com/article/103052/text
- Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: The human N-glycome.
 Biochimica et Biophysica Acta General Subjects. 2016;1860(8):1574–82.
- Gornik O, Pavić T, Lauc G. Alternative glycosylation modulates function of IgG and other
 proteins implications on evolution and disease. Biochim Biophys Acta. 2012
 Sep;1820(9):1318–26.
- 507 11. Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases.
 508 Cellular Immunology. 2018;
- 509 12. Dall'Olio F. Glycobiology of aging. In: Subcellular Biochemistry. 2018.
- Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans Are a Novel
 Biomarker of Chronological and Biological Ages. The Journals of Gerontology: Series A.
 2014 Jul;69(7):779–89.
- Štambuk J, Nakić N, Vučković F, Pučić-Baković M, Razdorov G, Trbojević-Akmačić I, et al.
 Global variability of the human IgG glycome [Internet]. Biochemistry; 2019 Feb [cited
 2020 Jan 31]. Available from: http://biorxiv.org/lookup/doi/10.1101/535237

- 516 15. Menni C, Gudelj I, MacDonald-Dunlop E, Mangino M, Zierer J, Bešić E, et al.
- 517 Glycosylation Profile of Immunoglobulin G Is Cross-Sectionally Associated with
 518 Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two Independent
 519 Cohorts. Circulation Research. 2018;122(11):1555–64.
- 16. Wittenbecher C, Štambuk T, Kuxhaus O, Rudman N, Vučković F, Štambuk J, et al. Plasma
 N-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation
 in the EPIC-Potsdam Cohort Study. Diabetes Care. 2020 Jan 7;43(3):661–8.
- 523 17. Gao Q, Dolikun M, Stambuk J, Wang H, Zhao F, Yiliham N, et al. Immunoglobulin G N524 Glycans as Potential Postgenomic Biomarkers for Hypertension in the Kazakh
 525 Population. Omics. 2017;21(7):380–9.
- Liu J, Dolikun M, Štambuk J, Trbojević-Akmačić I, Zhang J, Wang H, et al. The association
 between subclass-specific IgG Fc N-glycosylation profiles and hypertension in the
 Uygur, Kazak, Kirgiz, and Tajik populations. J Hum Hypertens. 2018 Sep;32(8–9):555–63.
- Wang Y, Klarić L, Yu X, Thaqi K, Dong J, Novokmet M, et al. The Association Between
 Glycosylation of Immunoglobulin G and Hypertension: A Multiple Ethnic Cross-Sectional
 Study. Medicine. 2016 Apr;95(17):e3379.
- 532 20. Nikolac Perkovic M, Pucic Bakovic M, Kristic J, Novokmet M, Huffman JE, Vitart V, et al.
 533 The association between galactosylation of immunoglobulin G and body mass index.
 534 Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2014 Jan;48:20–5.
- Russell AC, Kepka A, Trbojević-Akmačić I, Ugrina I, Song M, Hui J, et al. Increased central
 adiposity is associated with pro-inflammatory immunoglobulin G N-glycans.
 Immunobiology. 2019;224(1):110–5.
- Sundgren NC, Vongpatanasin W, Boggan BMD, Tanigaki K, Yuhanna IS, Chambliss KL, et
 al. IgG receptor FcγRIIB plays a key role in obesity-induced hypertension. Hypertension.
 2015 Feb 21;65(2):456–62.
- Tanigaki K, Sacharidou A, Peng J, Chambliss KL, Yuhanna IS, Ghosh D, et al.
 Hyposialylated IgG activates endothelial IgG receptor Fc**y**RIIB to promote obesityinduced insulin resistance. J Clin Invest. 2018 Jan 2;128(1):309–22.
- 24. Peng J, Vongpatanasin W, Sacharidou A, Kifer D, Yuhanna IS, Banerjee S, et al.
 Supplementation with the Sialic Acid Precursor N-acetyl-D-Mannosamine Breaks the
 Link Between Obesity and Hypertension. 2019.
- 547 25. Tijardović M, Marijančević D, Bok D, Kifer D, Lauc G, Gornik O, et al. Intense Physical
 548 Exercise Induces an Anti-inflammatory Change in IgG N-Glycosylation Profile. Frontiers
 549 in Physiology. 2019;10(December):1–10.
- S50 26. Nguyen NT, Kim E, Vu S, Phelan M. Ten-year Outcomes of a Prospective Randomized
 S51 Trial of Laparoscopic Gastric Bypass Versus Laparoscopic Gastric Banding. Ann Surg.
 S52 2018;268(1):106–13.

- 553 27. O'Brien P. Bariatric surgery and type 2 diabetes: a step closer to defining an optimal 554 approach. The Lancet Diabetes & Endocrinology. 2019 Dec 1;7(12):889–91.
- Verdi S, Abbasian G, Bowyer RCE, Lachance G, Yarand D, Christofidou P, et al. TwinsUK:
 The UK Adult Twin Registry Update. Twin Res Hum Genet. 2019 Dec;22(6):523–9.
- Pavić T, Dilber D, Kifer D, Selak N, Keser T, Ljubičić Đ, et al. N-glycosylation patterns of
 plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease. J
 Transl Med. 2018 Nov 21;16.
- 30. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing
 batch effects and other unwanted variation in high-throughput experiments.
 Bioinformatics. 2012 Mar 15;28(6):882–3.
- 31. R Core Team (2020). R: A language and environment for statistical computing. R
 Foundation for Statistical Computing, Vienna, Austria. URL https://www.Rproject.org/.
- 566 32. Clerc F, Reiding KR, Jansen BC, Kammeijer GSM, Bondt A, Wuhrer M. Human plasma
 567 protein N-glycosylation. Glycoconj J. 2016 Jun 1;33(3):309–43.
- 33. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using
 Ime4. Journal of Statistical Software. 2015 Oct 7;67(1):1–48.
- S70 34. Clerc F, Novokmet M, Dotz V, Reiding KR, de Haan N, Kammeijer GSM, et al. Plasma NS71 Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases.
 S72 Gastroenterology. 2018;155(3):829–43.
- 35. Novokmet M, Lukić E, Vučković F, –Durić Ž, Keser T, Rajšl K, et al. Changes in IgG and
 total plasma protein glycomes in acute systemic inflammation. Scientific Reports. 2014
 Mar 11;4(1):1–10.
- 576 36. lida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of
 577 the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non578 fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009 Feb 18;9:58.
- 579 37. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-Inflammatory Activity of Immunoglobulin G
 580 Resulting from Fc Sialylation. Science. 2006 Aug 4;313(5787):670–3.
- 38. Sarin HV, Gudelj I, Honkanen J, Ihalainen JK, Vuorela A, Lee JH, et al. Molecular
 Pathways Mediating Immunosuppression in Response to Prolonged Intensive Physical
 Training, Low-Energy Availability, and Intensive Weight Loss. Front Immunol.
 2019;10:907.
- 39. Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, et al. Inhibition of
 endoplasmic reticulum-resident glucosidases impairs severe acute respiratory
 syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by
 altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob Agents
 Chemother. 2015 Jan;59(1):206–16.